Theranostic dosimetry using 86Y has been performed for pharmaceuticals such as DOTATOC 34,40, trastuzumab (an anti-HER2/neu mAb for ovarian carcinomas) 40, and PSMA targeting compounds 41. The gene discussed is ERBB2; the disease is ovarian carcinoma.